You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Penitrem A
Penitrem A is a potent and selective blocker of BKCa (KCa1.1) channels (IC50 values are 6.4 and 64.4 nM for BKCa channels containing α subunits only, and those containing α and β1 respectively). Displays no effect on native delayed rectifier K+ and KATP currents, or cloned KV1.5 channels. Blocks BKCa channels in both inside-out and cell-attached patches. Shown to enhance smooth muscle contraction in vitro and increase total peripheral resistance in vivo.
Technical Data for Penitrem A
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Penitrem A
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Penitrem A
The following data is based on the product molecular weight 634.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||15.77 mL||78.84 mL||157.68 mL|
|0.5 mM||3.15 mL||15.77 mL||31.54 mL|
|1 mM||1.58 mL||7.88 mL||15.77 mL|
|5 mM||0.32 mL||1.58 mL||3.15 mL|
References for Penitrem A
References are publications that support the biological activity of the product.
Asano et al (2012) Penitrem A as a tool for understanding the role of large conductance Ca2+/voltage-sensitive K+ channels in vascular function. J.Pharmacol.Exp.Ther. 342 453 PMID: 22580348
Knaus et al (1994) Tremorgenic indole alkaloids potently inhibit smooth muscle high-conductance calcium-activated potassium channels. Biochemistry 33 5819 PMID: 7514038
If you know of a relevant reference for Penitrem A, please let us know.
View Related Products by Product Action
Keywords: Penitrem A, Penitrem A supplier, PenitremA, maxi-k, bk, channels, potent, selective, inhibitors, inhibits, blockers, slo, KCa, KCa1.1, K+, high, conductance, Ca2+-dependent, Potassium, Ca2+-activated, Ca2+-Activated, Channels, 4617, Tocris Bioscience
3 Citations for Penitrem A
Citations are publications that use Tocris products. Selected citations for Penitrem A include:
Khan et al (2019) BK channels regulate extracellular Tat-mediated HIV-1 LTR transactivation. Sci Rep 9 12285 PMID: 31439883
Hirono et al (2015) BK Channels Localize to the Paranodal Junction and Regulate Action Potentials in Myelinated Axons of Cerebellar Purkinje Cells. J Biol Chem 35 7082 PMID: 25948259
Abrahao et al (2017) Ethanol-Sensitive Pacemaker Neurons in the Mouse External Globus Pallidus. Neuropsychopharmacology 42 1070 PMID: 27827370
Do you know of a great paper that uses Penitrem A from Tocris? Please let us know.
Reviews for Penitrem A
Average Rating: 4 (Based on 1 Review.)
Have you used Penitrem A?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Product used to understand BK channel blocking activity on HEK 293 cell line.The cell line expresses brain alpha subunits of BK channel. Showed blocking activity on electrophysiological tests. Product worked ideally and would definitely worth buying.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.